Correction of hyperphosphatemia in hemodialysis patients: 12-month findings from a randomized study
| Autor: | I.O. Dudar, O.M. Loboda, E.K. Krasyuk, S.L. Dudar |
|---|---|
| Jazyk: | English<br />Ukrainian |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Український Журнал Нефрології та Діалізу, Iss 3(75) (2022) |
| Druh dokumentu: | article |
| ISSN: | 2304-0238 2616-7352 |
| DOI: | 10.31450/ukrjnd.3(75).2022.08 |
| Popis: | Abstract. The aim of our study was to compare the safety and effectiveness of the use of sevelamer with calcium acetate for hyperphosphatemia control in hemodialysis patients. Materials and methods. An open-label, randomized, parallel study was conducted to compare the safety and effectiveness of the use of sevelamer with calcium acetate for hyperphosphatemia control in hemodialysis patients. 198 patients treated with hemodialysis at the Kyiv City Center of Nephrology and Dialysis in the period from 2019 to 2021 were included. The duration of the study was 12 months. with a 2-week washout period before starting the study. Before the start of the study, any phosphate binders were withdrawn. After a 2-week washout period, patients were randomized to receive sevelamer or calcium acetate. The primary endpoint of the study was death from any cause, the surrogates were death from cardiovascular events, and the incidence of fractures. Results. At the end of the follow-up period, 86 (93%) of the 92 patients who remained alive (main group) had the target serum phosphorus level. At the end of treatment, the level of phosphorus in the main group was 1.62 (1.4, 1.67) mmol/l (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|